Analytical Data
-
基因名
KYNU
- Application
-
别名
KYNU；Kynureninase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q16719
-
表达区间
1-307aa
-
氨基酸序列
MEPSSLELPADTVQRIAAELKCHPTDERVALHLDEEDKLRHFRECFYIPKIQDLPPVDLSLVNKDENAIYFLGNSLGLQPKMVKTYLEEELDKWAKIAAYGHEVGKRPWITGDESIVGLMKDIVGANEKEIALMNALTVNLHLLMLSFFKPTPKRYKILLEAKAFPSDHYAIESQLQLHGLNIEESMRMIKPREGEETLRIEDILEVIEKEGDSIAVILFSGVHFYTGQHFNIPAITKAGQAKGCYVGFDLAHAVGNVELYLHDWGVDFACWCSYKYLNAGAGGIAGAFIHEKHAHTIKPARSEFFN
-
分子量
61.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KYNU, or Kynureninase, is an enzyme involved in the kynurenine pathway, a crucial metabolic route that links tryptophan metabolism to the production of various bioactive metabolites, including kynurenine and quinolinic acid. Research into KYNU is gaining traction due to its significant role in neurobiology and immunology, as the metabolites produced in this pathway are implicated in numerous physiological and pathological processes, including neurodegenerative diseases, depression, and immune responses. Dysregulation of KYNU activity has been associated with various disorders, making it a potential therapeutic target. The recombinant expression of KYNU allows researchers to produce the enzyme in a controlled laboratory setting, facilitating detailed studies on its structure, function, and regulatory mechanisms. This can enhance our understanding of its role in health and disease and aid in the development of novel therapeutic strategies aimed at modulating the kynurenine pathway. The ability to produce well-characterized KYNU also paves the way for high-throughput screening of potential inhibitors or activators, which could lead to innovative treatments for conditions linked to imbalances in this metabolic pathway.
